Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3459 |
Name | breast carcinoma |
Definition | A breast cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer breast carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
RB1 mut TP53 mut | R547 | breast carcinoma | sensitive | detail... |
RB1 wild-type TP53 mut | R547 | breast carcinoma | sensitive | detail... |
RB1 wild-type TP53 wild-type | R547 | breast carcinoma | sensitive | detail... |
PIK3CA E545K | XL147 | breast carcinoma | sensitive | detail... |
FGFR2 pos FGFR3 pos | E7090 | breast carcinoma | sensitive | detail... |
TP53 mutant | Camptothecin + CHIR-124 | breast carcinoma | predicted - sensitive | detail... |
TP53 inact mut | CHIR-124 + Irinotecan | breast carcinoma | predicted - sensitive | detail... |
TP53 inact mut | CHIR-124 + SN-38 | breast carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
NCT01293032 | Phase I | Tamoxifen | Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer | Completed | USA | CAN | 0 |
NCT01466972 | Phase II | Pazopanib | Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib | Completed | USA | 0 |
NCT01864746 | Phase III | Palbociclib | A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery (PENELOPE-B) | Completed | USA | IRL | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 2 |
NCT01945775 | Phase III | Gemcitabine Capecitabine Vinorelbine Talazoparib Eribulin | A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA) | Completed | USA | POL | ITA | ISR | IRL | GBR | FRA | ESP | DEU | BRA | BEL | AUS | 4 |
NCT01952054 | Phase II | Denosumab | Denosumab for Breast Cancer With Bone Mets | Terminated | USA | 0 |
NCT02034916 | Phase II | Talazoparib | A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) | Terminated | USA | GBR | FRA | ESP | DEU | 0 |
NCT02270372 | Phase I | Varlilumab ONT-10 | Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer | Completed | USA | 0 |
NCT02278965 | Phase I | Metformin | Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer | Completed | USA | 0 |
NCT02436993 | Phase II | Bevacizumab Pertuzumab + Trastuzumab Carboplatin + Paclitaxel | Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | Active, not recruiting | USA | 0 |
NCT02454972 | Phase II | Lurbinectedin | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | Completed | USA | SWE | ITA | GBR | FRA | ESP | DEU | CHE | BEL | 0 |
NCT02658812 | Phase II | Talimogene laherparepvec | Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT02960594 | Phase I | INO-1400 + INO-9012 INO-1400 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse | Completed | USA | 0 |
NCT03004534 | Phase 0 | Darolutamide | A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of ODM-201 | Completed | USA | DEU | CAN | 0 |
NCT03182634 | Phase II | Fulvestrant Ceralasertib + Olaparib Capivasertib Fulvestrant + Neratinib | The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial (plasmaMATCH) | Unknown status | GBR | 0 |
NCT03238196 | Phase I | Erdafitinib + Fulvestrant + Palbociclib | Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer | Completed | USA | 0 |
NCT03238495 | Phase II | Carboplatin + Docetaxel + Pertuzumab + Trastuzumab Carboplatin + Docetaxel + Metformin + Pertuzumab + Trastuzumab | Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer (HERMET) | Unknown status | USA | 0 |
NCT03238703 | FDA approved | Tamoxifen Exemestane Toremifene Anastrozole Letrozole | Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer | Withdrawn | USA | 0 |
NCT03747042 | Phase I | Letrozole | Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer | Active, not recruiting | USA | 0 |
NCT03861403 | Phase Ib/II | Avelumab + Cyclophosphamide + TRX518 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03916744 | Phase I | Giredestrant | A Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer | Completed | USA | GBR | ESP | BEL | AUS | 0 |
NCT03957096 | Phase I | SGN-CD47M | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03962647 | Phase I | Letrozole | A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer | Completed | USA | 0 |
NCT04054752 | Phase I | NT-I7 | Vaccine Response With NT-I7 | Withdrawn | USA | 0 |
NCT04294225 | Phase II | Anastrozole + Letrozole | Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer | Completed | USA | 0 |
NCT04393298 | Phase Ib/II | UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 | A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | Completed | USA | GBR | 0 |
NCT04425018 | Phase II | Paclitaxel + Pertuzumab + Trastuzumab Margetuximab-cmkb + Paclitaxel + Pertuzumab | MARGetuximab Or Trastuzumab (MARGOT) (MARGOT) | Active, not recruiting | USA | 0 |
NCT04529044 | Phase II | lutetium Lu 177 dotatate | 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer | Unknown status | USA | 0 |
NCT04553770 | Phase II | Trastuzumab deruxtecan Anastrozole + Trastuzumab deruxtecan | Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | Recruiting | USA | 0 |
NCT05143970 | Phase I | IPH5301 IPH5301 + Paclitaxel + Trastuzumab | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES) | Recruiting | FRA | 0 |
NCT05163041 | Phase Ib/II | BT7480 BT7480 + Nivolumab | Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | Recruiting | USA | GBR | 0 |
NCT05576077 | Phase I | Pembrolizumab + TBio-4101 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING) | Recruiting | USA | CAN | 0 |
NCT05949424 | FDA approved | Lenvatinib Olaparib Pazopanib Palbociclib Sunitinib | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (OPTI-DOSE) | Not yet recruiting | NLD | 0 |
NCT06120075 | Phase I | AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) | Recruiting | USA | 0 |
NCT06157892 | Phase Ib/II | Disitamab vedotin + Tucatinib Disitamab vedotin | A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors | Recruiting | USA | ITA | GBR | ESP | CAN | AUS | 1 |
NCT06390241 | Phase I | Yttrium Y 90-DOTA-biotin | Avidination for RadionuclideTHerapy in Nonpalpable Breast Cancer (ARTHE) | Recruiting | ITA | 0 |
NCT06444815 | Phase I | VET3-TGI Pembrolizumab + VET3-TGI | A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001) | Recruiting | USA | 0 |